Mass-production and characterization of anti-CD20 monoclonal antibody in peritoneum of Balb/c mice
View/ Open
Date
2013Author
Sineh Sepehr, K
Baradaran, B
Majidi, J
Abdolalizadeh, J
Aghebati, L
Shahneh, FZ
Metadata
Show full item recordAbstract
Purpose: Monoclonal antibodies are important tools are used in basic research as well as, in diagnosis, imaging and treatment of immunodeficiency diseases, infections and cancers. The purpose of this study was to produce large scale of monoclonal antibody against CD20 in order to diagnostic application in leukemia and lymphomas disorders. Methods: Hybridoma cells that produce monoclonal antibody against human CD20 were administered into the peritoneum of the Balb/c mice which have previously been primed with 0.5 ml Pristane. After twelve days, approximately 7 ml ascetic fluid was harvested from the peritoneum of each mouse. Evaluation of mAb titration was assessed by ELISA method. In the present study, we describe a protocol for large scale production of MAbs. Results: We prepared monoclonal antibodies (mAbs) with high specificity and sensitivity against human CD20 by hybridoma method and characterized them by ELISA. The subclass of antibody was IgG2a and its light chain was kappa. Ascetic fluid was purified by Protein-A Sepharose affinity chromatography and the purified monoclonal antibody was conjugated with FITC and Immunofluorescence was done for confirming the specific binding. Conclusion: The conjugated monoclonal antibody could have application in diagnosis B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. é 2013 by Tabriz University of Medical Sciences.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies
Majidi, J; Barar, J; Baradaran, B; Abdolalizadeh, J; Omidi, Y (2009)In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the ... -
Antibody humanization methods for development of therapeutic applications
Ahmadzadeh, V; Farajnia, S; Feizi, MAH; Nejad, RAK (2014)Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, the immunogenicity of murine-derived monoclonal antibodies is restrictive in cancer immunotherapy. Humanized ... -
A novel monoclonal antibody against a synthetic peptide from ?-actin can react with its corresponding protein
Amini, N; Bayat, A-A; Zarei, O; Hadavi, R; Mahmoudian, J; Mahmoudi, AR; Darzi, M; Rabbani, H; Jeddi-Tehrani, M (2015)Actin is one of the most widely studied structural and multifunctional housekeeping proteins in eukaryotic cells with important roles in many cell functions. Antibodies against ?-actin and other housekeeping gene-encoded ...